Septerna’s SEP-631 Shows Dose-Dependent Skin Response in Phase 1 Urticaria Study
Septerna's SEP-631 demonstrates dose-dependent skin response in Phase 1 urticaria study, establishing mechanistic link to MRGPRX2 receptor occupancy in...
BioAge Labs Advances BGE-102 NLRP3 Inhibitor With Phase 2 Cardiovascular Trial
BioAge Labs advances BGE-102 NLRP3 inhibitor into Phase 2 cardiovascular trial after Phase 1 showed 86% median hsCRP reduction.
Actuate Advances Oral Elraglusib Into Phase 1/2 After FDA IND Clearance
Actuate advances oral elraglusib into Phase 1/2 after FDA IND clearance, targeting superior systemic exposure versus IV formulation.
MoonLake Gains FDA Clearance for Sonelokimab Hidradenitis Suppurativa Label
MoonLake's sonelokimab hidradenitis suppurativa treatment gains FDA clearance with the highest efficacy rates ever recorded in an adequate, well-controlled...
Intellia’s Lonvoguran Ziclumeran Cuts HAE Attacks 87% in Phase 3 Trial
Intellia's lonvoguran ziclumeran reduced HAE attacks 87% in Phase 3, with 62% of patients remaining attack-free for six months...
FDA Approves Efgartigimod for All Adult Generalized Myasthenia Gravis Types
FDA approves efgartigimod for all adult generalized myasthenia gravis types, including seronegative patients previously excluded from treatment labels.
CytomX Closes Dose Optimization for Varsetatug Masetecan, Eyes 2026 Data
CytomX closes dose optimization for varsetatug masetecan with 2H 2026 data readout expected to determine monotherapy selection and registrational...
Denali Pursues DNL593 Alone After Takeda Exit in GRN-FTD Program
Denali pursues DNL593 alone in GRN-FTD after Takeda's exit, with Phase 1/2 data expected before year-end in this genetically...
Artiva’s AlloNK Advances to Phase 3 Trial in Refractory Rheumatoid Arthritis
Artiva's AlloNK advances to Phase 3 trial in refractory rheumatoid arthritis with FDA-aligned design. 150-patient study compares allogeneic NK...
Atsena Advances XLRS and LCA1 Gene Therapies to Phase 3 Trials
Atsena advances XLRS and LCA1 gene therapies to Phase 3 trials, with foveal schisis closure maintained at 12 months...